搜尋
United Therapeutics Corp
UTHR添加自選
517.380USD
-8.440-1.61%
收盤 07-31 16:00（美東）報價延遲15分鐘
21.81B總市值
17.67本益比TTM
關於 United Therapeutics Corp 公司
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
United Therapeutics Corp簡介
公司代碼UTHR
公司名稱United Therapeutics Corp
上市日期Jun 17, 1999
CEORothblatt (Martine A)
員工數量1305
證券類型Ordinary Share
年結日Jun 17
公司地址1000 Spring St
城市SILVER SPRING
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編20910
電話13016089292
網址https://www.unither.com/
公司代碼UTHR
上市日期Jun 17, 1999
CEORothblatt (Martine A)
United Therapeutics Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
701.73K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
45.17K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
21.88K
+5.99%
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
21.39K
+87.62%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.68K
+11.45%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
4.44K
+14.64%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
3.24K
+20.06%
Ms. Jan Malcolm
Ms. Jan Malcolm
Director
Director
450.00
+72.22%
Mr. Raymond C. (Ray) Kurzweil, J.D.
Mr. Raymond C. (Ray) Kurzweil, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
701.73K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
45.17K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
21.88K
+5.99%
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
21.39K
+87.62%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.68K
+11.45%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
4.44K
+14.64%
常見問題
United Therapeutics Corp的前五大股東是誰？
United Therapeutics Corp的前五大股東如下：Dr. Martine A. Rothblatt
有多少機構持有United Therapeutics Corp(UTHR)的股份？
截至2026Q1，共有1548家機構持有United Therapeutics Corp的股份，合計持有的股份價值約為42.91M，占公司總股份的101.10% 。與2025Q4相比，機構持股有所增加，增幅為-1413631.00。
哪個業務部門對United Therapeutics Corp的收入貢獻最大？
在2026Q1，Tyvaso DPI業務部門對United Therapeutics Corp的收入貢獻最大，創收1.29B，占總收入的40.59% 。